Chapter
IIBA Launches New Chapter Platform Supporting Global Community Engagement
With 30,000 members and 120 chapters worldwide, IIBA leads the global business analysis community and professional standards, shaping the practice of business analysis to achieve better enterprise outcomes.
- With 30,000 members and 120 chapters worldwide, IIBA leads the global business analysis community and professional standards, shaping the practice of business analysis to achieve better enterprise outcomes.
- Work on migrating IIBA chapters to the new platform began in February and will be completed in November 2024.
- IIBA chapters are your global pass to analysis everywhere, as anyone in the world can attend a virtual chapter event to learn more about business analysis and its critical importance to organizations,” says Jared Gorai, Director, Chapters and Member Engagement at IIBA.
- For more information on IIBA chapters or the chapter engagement platform, please contact IIBA Customer Support at [email protected] .
GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update
GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of March 31, 2024 and provided a business update.
- GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of March 31, 2024 and provided a business update.
- Once the AAC/AAP program resumes, the Company estimates that the cash runway would be extended to the end of Q1 2025.
- GenSight successfully manufactured two Drug Substance (DS) batches of LUMEVOQ® meeting Good Manufacturing Practice (GMP) standards in September and November 2023.
- As of March 31, 2024, GenSight Biologics’ number of outstanding shares was 78,370,724 ordinary shares.
Analysis of Joint Venture Deals in Pharmaceuticals and Biotechnology Between 2016-2024 - ResearchAndMarkets.com
The "Joint Venture Deals in Pharmaceuticals and Biotechnology 2016-2024" report has been added to ResearchAndMarkets.com's offering.
- The "Joint Venture Deals in Pharmaceuticals and Biotechnology 2016-2024" report has been added to ResearchAndMarkets.com's offering.
- Joint Venture Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter joint venture deals.
- Fully revised and updated, the report provides details of joint venture deals from 2016 to 2024.
- Joint Venture Deals in Pharmaceuticals and Biotechnology includes:
In Joint Venture Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:
Distribution Deal Trends in Diagnostics Report 2024 with Analysis of Deals Signed Since 2016 - ResearchAndMarkets.com
The "Distribution Deals in Diagnostics 2016 to 2024" report has been added to ResearchAndMarkets.com's offering.
- The "Distribution Deals in Diagnostics 2016 to 2024" report has been added to ResearchAndMarkets.com's offering.
- Distribution Deals in Diagnostics provides a detailed understanding and analysis of how and why companies enter distribution deals.
- Fully revised and updated, the report provides details of distribution deals from 2016 to 2024.
- Distribution Deals in Diagnostics provides the reader with the following key benefits:
Directory of deals by company A-Z, therapy focus and technology type
Distribution Deals in Diagnostics includes:
In Distribution Deals in Diagnostics, the available deals are listed by:
Global Biotechnology Licensing Agreements Analysis Report 2024 with Directory of Deals Signed Since 2019 - ResearchAndMarkets.com
Licensing Deals in Biotechnology provides a detailed understanding and analysis of how and why companies enter licensing deals.
- Licensing Deals in Biotechnology provides a detailed understanding and analysis of how and why companies enter licensing deals.
- Fully revised and updated, the report provides details of licensing deals from 2019 to 2024.
- The deal directory includes a comprehensive listing of all licensing deals announced since 2019.
- Directory of deals by company A-Z, therapy focus and technology type
Licensing Deals in Biotechnology includes:
Analyzing contract agreements allows due diligence of:
What are the rights granted or optioned?
GenSight Biologics Reports Full Year 2023 Consolidated Financial Results
From 2022 to 2023, the Company's research and development expenses remained stable, at €19.3 million in 2022 and €19.4 million in 2023.
- From 2022 to 2023, the Company's research and development expenses remained stable, at €19.3 million in 2022 and €19.4 million in 2023.
- The Company's general and administrative expenses also remained stable and amounted to €5.4 million in 2022 and 2023.
- The weighted average number of shares outstanding increased from 46.3 million in 2022 to 48.3 million in 2023, thereby reducing the loss per share from (€0.54) in 2023 to (€0.60) in 2023.
- GenSight Biologics will report its cash position as of March 31, 2024 on April 4 2024.
Pharmaceutical and Biotechnology Royalty Rates Report and Directory 2024: Technology Licensed, License Fees, Upfront and Milestone Payments for Deals Signed Since 2020 - ResearchAndMarkets.com
Royalty Rates in Pharmaceutical and Biotechnology Deals is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.
- Royalty Rates in Pharmaceutical and Biotechnology Deals is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.
- This report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors.
- The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.
- Chapter 4 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates.
Biotechnology Collaboration Agreements Analysis Report 2024: Global Coverage, Deal Financials, Contract Documents, Deal Trends, Leading Dealmakers, Comprehensive Deal Directory 2019-2024 - ResearchAndMarkets.com
Collaboration Deals in Biotechnology provides a detailed understanding and analysis of how and why companies enter collaboration deals.
- Collaboration Deals in Biotechnology provides a detailed understanding and analysis of how and why companies enter collaboration deals.
- Fully revised and updated, the report provides details of collaboration deals from 2019 to 2024.
- The report provides access to collaboration deal payment terms as announced between the parties.
- Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the collaboration deal.
Pharmaceuticals and Biotechnology Asset Purchase Deal Trends Analysis Report and Directory 2024: Benchmark Data for Deals Signed Since 2016 by the World's Leading Life Science Companies - ResearchAndMarkets.com
Asset Purchase Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals.
- Asset Purchase Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals.
- The report provides access to asset purchase deal payment terms as announced between the parties.
- The report focuses on four primary types of asset available for purchase, business assets, product assets, royalty assets, and technology assets.
- The deal directory includes a comprehensive listing of all asset purchase deals announced since 2016.